Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue: −1.90%
EPS: −47.2%
Free cash flow: −30.3%
Total debt: −0.43%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

42.43 0.65 +1.56%

Follow TEVA

Alert me

Market cap: $48.7B
P/E: 92.6×
Fwd P/E: 30.7×
Dividend yield: —
F-score: 8/9
Altman Z: 0.79
Beneish M: −2.35
Dividend safety: 52/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. 10-K filed Feb 5, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 5, 2025 · accepted 4:09 PM ET · Document on sec.gov · Filing index

Red flags

Restatement Feb 5, 2025
Teva Pharmaceutical Industries Ltd.’s 10-K corrects an error in previously issued financial statements

10-K filed Feb 5, 2025 · The filing · sec.gov
Impairment Feb 5, 2025
Teva Pharmaceutical Industries Ltd. recorded a goodwill impairment of $280.0 million in fiscal 2024

10-K filed Feb 5, 2025 · The filing · sec.gov